Hit-to-Lead Capabilities
WuXi Biology provides services for hit identification and hit-to-lead programs. We undertake assay development in major target classes, such as GPCRs and transporters, kinases, and ion channels. Our screening capabilities span from cell line generation, biochemical, and cell-based functional assays.
Screening Platform to support Medicinal Chemistry
Major Target Classes
- Enzyme
- Immuno-oncology Checkpoint enzyme
- GPCR
- Nuclear Hormone Receptor
- Transporter
- Ion Channel
- Protein-protein Interaction
- Infectious disease targets
Major Assay platforms
- Fluorescence: FI, FP, HTRF, FRET, FLIPR
- Luminescence (e.g. luciferase, b-lactamase, deGFP, reporter gene)
- Absorbance
- HCS
- Radiometric assays (e.g. SPA, MicroBeta, Filtration)
- LC/MS
- Label free technology
- MSD, Luminex, ELISA
Major Phenotypic Assays
- Proliferation/Anti-proliferation
- Viability/Cytotoxicity
- Apoptosis
- Translocation
- Internalization/Recycling
- Cytokine Profiling
- Cellular Uptake
in vitro Toxicology Studies
WuXi Biology provides in vitro toxicology services which support early drug discovery and lead selection/optimization. As a continuation of plate-based efficacy services, we provide rapid and valuable safety evaluation to define the potential of new compounds in your pipeline.
New Modalities
WuXi Biology provides customized solutions that enable our partners to achieve success in drug discovery for challenging targets.
